Coronary artery bypass graft surgery (CABG),an important treatment modality in ischemic patients, increases myocardial perfusion and ejection fraction (EF) in patients with coronary artery diseases. Although the rapid reperfusion by CABG significantly reduces mortality and morbidity, this reperfusion paradoxically may contribute to acute inflammatory reaction by ischemic-reperfusion injury and endotoxemia that lead to left ventricle remodeling, myocardial stunning injuries and/or death after CABG. Therefore, new treatment modalities should focus on decreasing inflammation and damage after reperfusion. In addition to the protective effect of EPO on myocardial ischemia, studies on animal models have shown that EPO can also reduces reperfusion tissue injuries. Studies on human models have, however, proved somewhat controversial and some of them support high dose EPO cardioprotective effect. In this randomized, double-blind, clinical trial,the study population is comprised of 90 patients that are referred to Shahid Modarres Hospital (Tehran, Iran) for elective CABG .Patients will randomly divide into three groups: the intervention group 1, receiving standard medication and CABG surgery plus EPO (20,000 IU), the intervention group 2, receiving standard medication and CABG surgery plus EPO (60,000 IU),and the control group, receiving standard medication and CABG surgery plus normal saline as placebo.To evaluation the effect of EPO infusion on reducing ischemia-reperfusion injuries and improvement of cardiac function we asses inflammatory markers(IL-6,YKL-40,TNNF-a), BNP and ischemic markers(troponin and CK-MB).